ProMetic Secures $30 Million Follow-on Financing

ProMetic Life Sciences Inc. (TSX:PLI, OTCQX:PFSCF) has secured a follow-on investment from Structured Alpha LP, an affiliate of Peter J. Thomson’s investment firm, Thomvest Asset Management Inc., consisting of a $30 million original issue discount note.
Stefan Clulow, Managing Director and Chief Investment Officer at Thomvest Asset Management Inc. commented:

We are very pleased to provide more support to ProMetic as it continues to deliver on its operational and clinical milestones. Since our initial investment inSeptember 2013, ProMetic has transitioned from a development stage company to an integrated biopharmaceutical company that is advancing a broad array of small molecule and plasma-derived clinical assets. We are confident that ProMetic will be successful in monetizing its innovations and we look forward to participating further in the significant value creation we see unfolding as ProMetic’s product pipeline continues to grow and approach the commercialization stage.

Commenting on Structured Alpha’s follow-on investment, Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc., said:

We are delighted that Mr. Thomson has decided to deepen his relationship with ProMetic. Our strategic relationship has already allowed for the operational launch of our plasma purification facility, the accelerated development of our plasma derived and small molecule technology platforms and advancement of our clinical programs. We look forward to leveraging this follow-on investment to generate value for all our shareholders.

Click here to view the full press release.